Gourzoulidis, G.; Kastanioti, C.; Mavridoglou, G.; Kotsilieris, T.; Tsolakidis, A.; Mathioudakis, K.; Voudigaris, D.; Tzanetakos, C.
Real-World Prevalence, Treatment Patterns, and Economic Impact of EGFR- and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Analysis from Greece. Curr. Oncol. 2025, 32, 542.
https://doi.org/10.3390/curroncol32100542
AMA Style
Gourzoulidis G, Kastanioti C, Mavridoglou G, Kotsilieris T, Tsolakidis A, Mathioudakis K, Voudigaris D, Tzanetakos C.
Real-World Prevalence, Treatment Patterns, and Economic Impact of EGFR- and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Analysis from Greece. Current Oncology. 2025; 32(10):542.
https://doi.org/10.3390/curroncol32100542
Chicago/Turabian Style
Gourzoulidis, George, Catherine Kastanioti, George Mavridoglou, Theodore Kotsilieris, Anastasios Tsolakidis, Konstantinos Mathioudakis, Dikaios Voudigaris, and Charalampos Tzanetakos.
2025. "Real-World Prevalence, Treatment Patterns, and Economic Impact of EGFR- and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Analysis from Greece" Current Oncology 32, no. 10: 542.
https://doi.org/10.3390/curroncol32100542
APA Style
Gourzoulidis, G., Kastanioti, C., Mavridoglou, G., Kotsilieris, T., Tsolakidis, A., Mathioudakis, K., Voudigaris, D., & Tzanetakos, C.
(2025). Real-World Prevalence, Treatment Patterns, and Economic Impact of EGFR- and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Analysis from Greece. Current Oncology, 32(10), 542.
https://doi.org/10.3390/curroncol32100542
